Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA)

Impact · against what's priced in

NMRA faces a severe valuation reset following the failure of its primary drug candidate and subsequent workforce reductions. The initiation of a securities investigation adds a secondary layer of legal risk and potential liability to an already distressed operational outlook.

NMRA−1.00

No priced-in read yet